908 Devices Inc (MASS)

908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 2, 2026 4:30 PM
Business Wire 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices’ common stock. The options were granted as a material inducement to employment with 908 Devices Inc. in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the 908 Devices Inc. 2026 Inducement Plan (the “Plan”). The inducement stock option has an exercise price of $8.63 per share, which is equal to the closing price of 908 Devices’ common stock on the grant date of June 1, 2026. The inducement stock option vests over four years with 25% of the shares vesting on the first anniversary of the grant date, and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service through each applicable vesting date. The foregoing inducement awards are subject to the terms and conditions of the Plan, and the terms and conditions of the applicable award agreements covering the grant. About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit 908devices.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602174982/en/ IR & Media Contact
Barbara Russo
IR@908devices.com Original: 908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue OutlookMay 6, 2026 7:30 AM
Business Wire Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR Acquired NIRLAB AG, expanding narcotics identification capabilities 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segment of the narcotics detection market while increasing our recurring revenue opportunity through software subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy.” Recent Highlights Revenue of $13.4 million for the first quarter of 2026, increasing 14% year over year Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter Gross margin was 51% and Adjusted gross margin was 57% for the first quarter of 2026, a 290-basis point improvement in Adjusted gross margin compared to the first quarter of 2025 Ended the quarter with a strong balance sheet, with a cash position of $111.7 million, consuming less than $1.5 million in the first quarter Subsequent to quarter end, acquired NIRLAB AG, bringing complementary drug detection capabilities, more international mix, and a high-retention recurring subscription model First Quarter 2026 Financial Results Revenue was $13.4 million for the three months ended March 31, 2026, a 14% increase over the prior year period, driven by an increase in product revenue for mass spec, from an increase in placements, and from a shift in FTIR product mix. OEM and funded partnership revenue was $0.6 million for the current and prior year period. The installed base grew 23% year-over-year to 3,903 devices, with 167 devices placed during the first quarter. Recurring revenue represented 30% of total revenues in the quarter. Gross profit was $6.9 million for the first quarter of 2026, compared to $5.5 million for the corresponding period in the prior year. GAAP gross margin was 51% as compared to 47% for the corresponding prior year period. Adjusted gross profit was $7.7 million for the first quarter of 2026, compared to $6.4 million for the corresponding period in the prior year. Adjusted gross margin was 57%, as compared to 54% for the corresponding prior year period. The increase in adjusted gross margin percentage was primarily driven by higher product revenues, including a shift in channel mix, along with the favorable impact of consolidated facilities, offset in part by lower service gross margins. Operating expenses were $19.8 million for the first quarter of 2026, compared to $16.6 million for the corresponding prior year period. The increase of $3.2 million includes a noncash increase of $3.9 million related to a change in the fair value of the contingent consideration liability, and a $0.7 million reduction of operating expenses related to research and development and selling, general, and administrative costs. Net loss from continuing operations was $12.0 million for the first quarter of 2026, compared to a net loss from continuing operations of $9.8 million for the corresponding prior year period. Adjusted EBITDA was a loss of $2.5 million for the first quarter of 2026, compared to a loss of $4.6 million for the corresponding period in the prior year. Net loss attributable to common stockholders was $12.0 million for the first quarter of 2026, compared to net income of $43.6 million for the corresponding prior year period. The income was related to the divestiture of our bioprocessing product portfolio which resulted in a gain of $56.6 million, net of transaction costs, and was also offset by a loss from discontinued operations for the first two months of the first quarter of 2025. Cash, cash equivalents and marketable securities were $111.7 million as of March 31, 2026, with no debt outstanding. 2026 Guidance 908 Devices now expects full year 2026 revenues to be in the range of $67.0 million to $70.0 million, representing 19% to 25% growth compared to 2025 revenue. Webcast Information 908 Devices will host a conference call to discuss the first quarter 2026 financial results before market open on Wednesday, May 6, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com. Non-GAAP Measures of Financial Performance To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below: Adjusted gross profit is defined as gross profit excluding intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), and non-cash expenses related to stock-based compensation. Adjusted gross margin is defined as adjusted gross profit expressed as a percentage of total revenue. Adjusted EBITDA is defined as net income (loss) from continuing operations excluding other income, benefit for income taxes, depreciation, intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), non-cash expenses related to stock-based compensation, and costs associated with contingent consideration related to the Company’s acquisitions and for which the conditions for payment have not yet been achieved. The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business. Forward Looking Statements This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth and the benefits of the Company’s acquisition of NIRLAB. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (SEC) which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law. 908 DEVICES INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited)                   Three Months Ended March 31,     2026   2025 Revenue:             Product revenue   $ 10,737     $ 8,529   Service and contract revenue     2,644       3,248   Total revenue     13,381       11,777   Cost of revenue:             Product cost of revenue     5,160       4,725   Service and contract cost of revenue     1,339       1,511   Total cost of revenue     6,499       6,236   Gross profit     6,882       5,541   Operating expenses:             Research and development     3,471       3,829   Selling, general and administrative     9,914       10,239   Change in fair value of contingent consideration     6,381       2,499   Total operating expenses     19,756       16,567   Loss from continuing operations     (12,884 )     (11,026 ) Other income, net     929       1,189   Net loss from continuing operations     (11,955 )     (9,837 ) Net income from discontinued operations, net of tax     —       53,440   Net income (loss) attributable to common stockholders   $ (11,955 )   $ 43,603   Net income (loss) from continuing operations per share attributable to common stockholders, basic and diluted   $ (0.32 )   $ (0.28 ) Net income from discontinued operations per share attributable to common stockholders, basic and diluted   $ —     $ 1.51   Net income (loss) per share attributable to common stockholders, basic and diluted   $ (0.32 )   $ 1.23       Basic and diluted   36,818,481     35,386,483   908 DEVICES INC. Condensed Consolidated Balance Sheets (in thousands) (unaudited)                   March 31,   December 31,     2026   2025 Assets             Current assets:             Cash, cash equivalents and marketable securities   $ 111,742   $ 112,970 Accounts receivable, net     9,865     11,327 Inventory     13,240     12,990 Prepaid expenses and other current assets     7,167     7,272 Total current assets     142,014     144,559 Operating lease, right-of-use assets     4,205     4,397 Property and equipment, net     4,141     4,232 Intangible, net     35,679     36,412 Other long-term assets     656     471 Total assets   $ 186,695   $ 190,071 Liabilities and Stockholders' Equity             Current liabilities:             Accounts payable and accrued expenses   $ 7,084   $ 8,424 Deferred revenue     9,470     8,934 Operating lease liabilities and other liabilities     23,106     16,706 Total current liabilities     39,660     34,064 Deferred revenue, net of current portion     9,068     8,331 Other long-term liabilities     3,796     3,977 Total liabilities     52,524     46,372 Total stockholders' equity     134,171     143,699 Total liabilities and stockholders' equity   $ 186,695   $ 190,071 908 DEVICES INC. Reconciliations of GAAP to Non-GAAP Financial Measures (Unaudited, amounts in thousands, except percentage and per share data) In all tables below, totals may not add due to rounding Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:                   Three Months Ended     March 31,     2026   2025               Gross Profit (GAAP)   $ 6,881     $ 5,541                 Intangible amortization     635       635   Acquisition and integration costs     -       50   Restructuring     -       66   Stock-based compensation     155       117                 Adjusted Gross Profit (Non-GAAP)   $ 7,671     $ 6,409                 Gross Margin Percentage (GAAP)     51 %     47 %               Adjusted Gross Margin Percentage (Non-GAAP)     57 %     54 %               Reconciliation from Net Loss from Continuing Operations (GAAP) to Adjusted EBITDA (Non-GAAP):                   Three Months Ended     March 31,     2026   2025               Net Loss from continuing operation (GAAP)   $ (11,955 )   $ (9,838 )               Adjustments:             Other income, net     (929 )     (1,188 ) Depreciation     406       291   Intangible amortization     732       713   Acquisition and integration costs     438       640   Restructuring     -       93   Stock-based compensation     2,399       2,221   Change in fair value of contingent consideration     6,381       2,499           Adjusted EBITDA (Non-GAAP)   $ (2,528 )   $ (4,569 )   View source version on businesswire.com: https://www.businesswire.com/news/home/20260506856828/en/ Investor and Media Contact:
Barbara Russo
IR@908devices.com Original: 908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026May 1, 2026 8:30 AM
Business Wire
908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time.


Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.


About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260501692729/en/
IR & Media

Barbara Russo

IR@908devices.com


Original: 908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026

908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 21, 2026 5:00 PM
Business Wire
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications.


Mr. Otitoju brings over 25 years of proven executive leadership in strategy, business development, and P&L management across the medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of Strategy & Business Development at Repligen Corporation, where he led the company's global corporate strategy and executed more than 15 M&A transactions and strategic partnerships over six years, supporting the company's approximately 20% compound annual growth rate to over $700 million of revenues.


“We are thrilled to welcome Kola to 908 Devices as we build on the momentum of our 2.0 transformation and enter our next phase of growth,” said Kevin J. Knopp, CEO and Co-founder. “His exceptional track record in driving both organic and inorganic growth makes him the ideal leader to accelerate our strategic initiatives and deliver long-term shareholder value. M&A and industry partnerships have already been successful and integral to our strategy, and we intend to lean in further. Kola’s appointment reinforces this commitment and positions us to execute at an even higher level.”


Prior to Repligen, Mr. Otitoju held senior strategy and business development roles at Candela Medical (an Apax Partners portfolio company), Baxter International, and GE Healthcare, where he served as Managing Director and Head of Business Development. Earlier in his career, he spent eight years in investment banking at Credit Suisse and Bank of America Securities, advising on M&A transactions across healthcare, industrials, and technology sectors. Mr. Otitoju holds an MBA from Harvard Business School, a master’s degree in electrical engineering from Cornell University, and a bachelor’s degree in information systems from Imperial College, London.


Details on Inducement Grant of RSUs and Options


908 Devices also announces that, on April 21, 2026, the Compensation Committee of its Board of Directors granted an aggregate of 110,193 restricted stock units (RSUs) of 908 Devices and options to purchase an aggregate of 146,789 shares of 908 Devices’ common stock to Mr. Otitoju, its newly appointed Chief Business & Strategy Officer. The RSUs and options were granted as a material inducement to Mr. Otitoju’s employment with 908 Devices Inc. in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the 908 Devices Inc. 2026 Inducement Plan (the Plan).


The RSUs will vest equally over three years on May 1, 2027, May 1, 2028, and May 1, 2029 subject to Mr. Otitoju’s continued service with 908 Devices. The inducement stock option has an exercise price of $7.26 per share, which is equal to the closing price of 908 Devices’ common stock on the grant date of April 21, 2026. The inducement stock option vests over three years, with 1/3 of the shares vesting on May 1, 2027 and the remaining 2/3 vesting in 24 equal monthly installments thereafter, subject to continued service through each applicable vesting date. The foregoing inducement award is subject to the terms and conditions of the Plan, and the terms and conditions of the applicable award agreement covering the grant.


About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit 908devices.com.


Forward Looking Statements for 908 Devices

This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 9, 2026 and elsewhere in the Company’s filings with the SEC which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s Annual Reports and Quarterly Reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421913357/en/
Media & IR Contact

Barbara Russo

IR@908devices.com


Original: 908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

$MASS: Repligen purchases sending $MASS

Now at $3.30


We've announced that @Repligen has purchased our bioprocessing PAT portfolio including our MAVERICK, MAVEN, REBEL & ZipChip devices. We are now fully focused on serving vital health and safety applications with our newly expanded handheld device portfolio. https://t.co/8ayBstxGDp pic.twitter.com/GcOpPEMsvQ— 908 Devices (@908Devices) March 4, 2025


Nice moves but still a Net Operating Loss so I dont know if this will stick around.
Gotta get those expenses under control.


GO $MASS

Transaction Terms and Advisors

The purchase consideration is a payment of $70 million in cash. Centerview Partners LLC is acting as financial advisor and Goodwin Procter is serving as legal counsel to Repligen Corporation. Perella Weinberg Partners is acting as financial advisor and Paul Hastings LLP is serving as legal counsel to 908 Devices Inc.
https://www.businesswire.com/news/home/20250304869460/en

Transaction Terms and Advisors

The purchase consideration is a payment of $70 million in cash. Centerview Partners LLC is acting as financial advisor and Goodwin Procter is serving as legal counsel to Repligen Corporation. Perella Weinberg Partners is acting as financial advisor and Paul Hastings LLP is serving as legal counsel to 908 Devices Inc.
https://www.businesswire.com/news/home/20250304869460/en

MASS ready for 3.40

MASS MONSTER

MASS GOING TO BE MASSIVE

Invisible works $2.42 + 20%

MASS, new 52 week low

MASS new 52 low

MASS new 52=week high

MASS new 52 week low

MASS new 52 week low

MASS 10Q due March 5

From that awful Cathie Wood
908 Devices (MASS)
icon-rise-1
22%
Shares of 908 Devices traded up ~22% on Tuesday after the company released5 its second-quarter results in which revenues rose 9% on a year-over-year basis, surprising on the high side of expectations. 908 Devices is a life sciences tools company that miniaturizes mass spectrometry to decentralize chemical and biomolecular analyses.